OncoSec to Present at Cowan and ROTH Healthcare Conferences

SAN DIEGO, CA, March 5, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon,President and CEO of OncoSec, will be presenting at the 32nd Annual Cowan Group Healthcare Conference March 5-7 in Boston, MA, and the 24th Annual Roth Conference, March 11-14 in Newport Beach. In addition, the company’s Phase II Merkel cell carcinoma program was featured in a news segment by a local NBC affiliate in Seattle, KIRO News 7, and the video can be viewed here.

The article, titled “The Treatment of Solid Tumors: Some Recent Approaches,” details some promising new strategies, including targeting tumors without affecting any of the surrounding healthy tissue using electroporation to deliver powerful cancer therapeutic agents, such as OncoSec’s OMS ElectroOncology therapies. The article also notes the urgent need to develop new treatments andoutlines some challenges of conventional approaches.

32nd Annual Cowan Group Healthcare Conference
The Boston Marriott Copley Place
Boston, MA
March 5-7, 2012

OncoSec Presentation
March 7, 2012
10:00 am ET

A live and archived webcast will be accessible on OncoSec’s website www.OncoSec.com. Please allow 15 minutes prior to the presentation to allow for anysoftware downloads.

24th Annual Roth Conference
The Ritz Carlton
1 Ritz Carlton Drive
Dana Point, CA 92629
March 11-14, 2012

OncoSec Presentation
March 14, 2012
8:00am PT

A live and archived webcast will be accessible on OncoSec’s website www.OncoSec.com. Please allow 15 minutes prior to the presentation to allow for anysoftware downloads.

To arrange a meeting with management please contact AdamHoldsworth,
The Investor Relations Group, LLC 212-285-3210 aholdsworth@investorrelationsgroup.com

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.